Home/Filings/5/0001493152-25-017839
5//SEC Filing

10X Fund, L.P. 5

Accession 0001493152-25-017839

CIK 0001133416other

Filed

Oct 9, 8:00 PM ET

Accepted

Oct 10, 6:27 PM ET

Size

9.2 KB

Accession

0001493152-25-017839

Insider Transaction Report

Form 5
Period: 2024-12-31
Transactions
  • Sale

    Common Stock

    2024-04-22$3.06/sh21,323$65,2485,925,884 total(indirect: By 10X Fund, LP)
  • Sale

    Common Stock

    2024-04-23$3.06/sh3,677$11,2525,922,207 total(indirect: By 10X Fund, LP)
Transactions
  • Sale

    Common Stock

    2024-04-22$3.06/sh21,323$65,2485,925,884 total(indirect: By 10X Fund, LP)
  • Sale

    Common Stock

    2024-04-23$3.06/sh3,677$11,2525,922,207 total(indirect: By 10X Fund, LP)
Footnotes (1)
  • [F1]10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Documents

1 file

Issuer

GALECTIN THERAPEUTICS INC

CIK 0001133416

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001453356

Filing Metadata

Form type
5
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 6:27 PM ET
Size
9.2 KB